- |||||||||| Zaltrap (ziv-aflibercept IV) / Sanofi
Trial primary completion date, HEOR, Combination therapy, Metastases: AFEQT: Colorectal Cancer Metastatic (clinicaltrials.gov) - Mar 14, 2015 P3, N=200, Active, not recruiting, Trial primary completion date: Dec 2014 --> Apr 2015
- |||||||||| Biomarker, Trial initiation date, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Mar 10, 2015
P2, N=610, Not yet recruiting, Recruiting --> Completed | Trial primary completion date: Jan 2012 --> Oct 2011 Initiation date: Jan 2015 --> Apr 2015 | Trial primary completion date: Nov 2020 --> May 2019
- |||||||||| leucovorin calcium / Generic mfg.
Trial primary completion date: A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) - Mar 3, 2015 P2, N=192, Recruiting, Trial primary completion date: Jan 2015 --> Jan 2017 Trial primary completion date: Sep 2015 --> Sep 2017
- |||||||||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer (clinicaltrials.gov) - Mar 3, 2015 P2, N=2, Terminated, Trial primary completion date: Sep 2015 --> Sep 2017 N=14 --> 2 | Recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Jul 2014; PI Decision
- |||||||||| conatumumab (AMG 655) / Amgen
Enrollment closed, Trial primary completion date: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Feb 20, 2015 P2, N=12, Active, not recruiting, N=240 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Apr 2015
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Metastases: Phase I Trial of Combination of FOLFIRI and SOM 230 (clinicaltrials.gov) - Feb 6, 2015 P1, N=16, Active, not recruiting, Active, not recruiting --> Completed Trial primary completion date: Aug 2015 --> Dec 2015
- |||||||||| Erbitux (cetuximab) / Eli Lilly
Enrollment change, Trial termination, Metastases: Colorectal Cancer (CRC) Cetuximab Elderly Frail (clinicaltrials.gov) - Jan 28, 2015 P2, N=5, Terminated, Trial primary completion date: Aug 2014 --> Aug 2015 N=150 --> 5 | Recruiting --> Terminated; poor accrual
|